Medical devices, healthcare technology and the business of care
PMA approval · P240040

Oncomine Dx Express Test

Life Technologies Corporation · Decision date Jul 2, 2025

FDA DECISIONP240040

What did the FDA approve?

FDA records P240040 as an original PMA application. The recorded decision is approval, dated Jul 2, 2025.

FDA approval order statement

Approval for the Oncomine Dx Express Test. The test is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing (NGS) technology to detect substitutions, insertions, and deletions in 42 genes from DNA, copy number variants (CNVs) in 10 genes from DNA, and fusions or splice variants in 18 genes from RNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor samples, using the Genexus Dx Integrated Sequencer. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapy listed in Table 1 in accordance with the approved therapeutic product labeling (see approval order for Table 1).Additionally, the test is intended to provide tumor mutation profiling information to be used by qualified health care professionals in accordance with professional guidelines in oncology for cancer patients with solid malignant neoplasms. Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Jul 2, 2025

FDA source record

Regulatory record facts

Identifier
P240040
Regulatory pathway
Premarket approval application
Product code
PQP
Decision code
APPR
Decision date
Jul 2, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240040 received

    Application receipt date recorded by FDA.

  2. P240040 · FDA decision

    APPR

  3. P240040/S005 · Related supplement

    Oncomine Dx Express Test

  4. P240040/S008 · Related supplement

    Oncomine Dx Express Test

Timeline entries are records held by MedtechLedger for P240040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240040

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementSep 9, 2026FDA
Life Technologies CorporationPMA supplementNov 4, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA
FoundationOne CDxP170019/S069
Foundation Medicine, Inc.PMA supplementSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Life Technologies Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7335 Executive Way, Frederick, MD, 21704

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records